<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The protective effects of the 21-aminosteroid tirilazad mesylate (U-74006F), one of the most efficacious inhibitors of free radical-initiated <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation, against ischemic brain damage particularly in permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> still remain controversial </plain></SENT>
<SENT sid="1" pm="."><plain>The present study was designed to determine the degree of neuroprotection produced by various doses of U-74006F in permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was achieved by permanent occlusion of the left middle cerebral artery in male Sprague-Dawley rats </plain></SENT>
<SENT sid="3" pm="."><plain>Four groups of rats were studied: viz </plain></SENT>
<SENT sid="4" pm="."><plain>vehicle-administered controls (n = 7), and U-74006F-treated animals at doses of 0.3 mg/kg (n = 7), 1.0 mg/kg (n = 7) and 3.0 mg/kg (n = 7) (i.v </plain></SENT>
<SENT sid="5" pm="."><plain>15 min, 2 h and 6 h post occlusion, and 3.3 times higher than the first 3 doses, i.p </plain></SENT>
<SENT sid="6" pm="."><plain>12 h post occlusion) </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty-four hours after surgery, the animals were subjected to neurological examination using a grading scale of 0 to 3, and sacrificed to assess ischemic damage by means of tetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> staining </plain></SENT>
<SENT sid="8" pm="."><plain>A dose-related attenuation of neurological deficits and ischemic damage was observed </plain></SENT>
<SENT sid="9" pm="."><plain>At the two highest doses, the volume of ischemic damage in the cerebral hemisphere was reduced by 25.3% (P &lt; 0.05) and 32.9% (P &lt; 0.005), compared to the controls </plain></SENT>
<SENT sid="10" pm="."><plain>The neurological deficit score for animals treated with U-74006F (3.0 mg/kg) was also significantly lower than for the controls (1.7 +/- 1.1 vs. 2.7 +/- 0.8; P &lt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>This study shows that U-74006F ameliorates postischemic neurologic deficits and provides dose-dependent neuroprotection against ischemic brain damage in focal <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
</text></document>